BSM-2300 &BSM6000 WITH CGS-9001 SERIES COMMUNICATION GATEWAY, MODEL CGS-9001 SERIES OPTIONAL ACCESSORY
K083271 · Nihon Kohden America, Inc. · MHX · Dec 24, 2008 · Cardiovascular
Device Facts
Record ID
K083271
Device Name
BSM-2300 &BSM6000 WITH CGS-9001 SERIES COMMUNICATION GATEWAY, MODEL CGS-9001 SERIES OPTIONAL ACCESSORY
Applicant
Nihon Kohden America, Inc.
Product Code
MHX · Cardiovascular
Decision Date
Dec 24, 2008
Decision
SESE
Submission Type
Special
Regulation
21 CFR 870.1025
Device Class
Class 2
Attributes
Software as a Medical Device, Pediatric
Intended Use
This device is intended to monitor, display and record physiological data to provide cardiac and vital signs monitoring within a medical facility. The device is intended to monitor the electrocardiogram and generate visible and/or audible alarms when an arrhythmia exists. The device is also intended to monitor heart rate, pulse rate, blood oxygen saturation (SpO2), noninvasive blood pressure (NIBP), invasive blood pressure (IBP), body temperature, carbon dioxide concentration (CO2 and EtCO2), and respiratory rate. The device may generate an audible and/or visible alarm when a measured rate falls outside preset limits. The device may also condition and transmit physiological signals via radio frequency. This will be available for use by medical personnel on all patient populations.
Device Story
BSM-2300A/BSM-6000 bedside monitors collect physiological data (ECG, SpO2, NIBP, IBP, temp, CO2, respiratory rate); CGS-9001A gateway accessory acts as software interface; collects alarm events from networked monitors; forwards data to third-party secondary alarm notification systems; used in medical facilities by medical personnel; enables remote alarm notification; improves patient safety by ensuring timely clinician awareness of critical physiological changes.
Clinical Evidence
Bench testing only. Safety and performance testing verified device operation within specifications. No clinical data required.
Technological Characteristics
Bedside patient monitoring system with optional software-based communication gateway. Connectivity: Networked via CGS-9001A for alarm data transfer to third-party systems. Signal transmission: Radio frequency. Compliance: IEC 601-1 sub-clause 56.2(c). Non-sterile; no direct patient contact for gateway accessory.
Indications for Use
Indicated for cardiac and vital signs monitoring in medical facilities for all patient populations. Monitors ECG, heart rate, pulse rate, SpO2, NIBP, IBP, temperature, CO2/EtCO2, and respiratory rate. Generates alarms for arrhythmias or out-of-limit vital signs.
Regulatory Classification
Identification
The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.
Special Controls
*Classification.* Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.
Predicate Devices
Nihon Kohden BSM-2300A Series Bedside Monitor (K011918)
K080342 — NIHON KOHDEN BEDSIDE MONITOR, MODEL BSM-6000S SERIES · Nihon Kohden America, Inc. · Feb 26, 2008
K101692 — PATIENT MONITOR · Contec Medical System Co., Ltd. · Jun 28, 2011
K151080 — Nihon Kohden CSM 1901 Bedside Monitor · Nihon Kohden · Nov 5, 2015
K082785 — NIHON KOHDEN BEDSIDE MONITOR, BSM 9100A SERIES · Nihon Kohden America, Inc. · Nov 26, 2008
K150329 — elance Vital Signs Monitor, Central Monitor Software · Spacelabs Healthcare · Nov 5, 2015
Submission Summary (Full Text)
{0}------------------------------------------------
### NIHON KOHDEN AMERICA, INC.
BSM-2300A & BSM-6000 Bedside Monitors with CGS-9001A Accessory
# KO83271
#### SECTION 2- 510(K) SUMMARY
Name and Address of Applicant Nihon Kohden America, Inc.
90 Icon Street Foothill Ranch, CA 92610
Contact: Jack Coggan Director, Regulatory Affairs (949) 580-1555 ex. 3325 Fax: (949) 580-1550
Trade/Device Name: BSM-2300 Series and BSM-6000 Series with CGS-9001A Series Communication Gateway Server Optional Accessory.
Common or usual Name: Bedside Monitor, Patient Monitor, Cardiac Monitor, Vital Signs Monitor, Anesthesia Monitor
Legally Marketed Predicate: Nihon Kohden BSM-2300A Series Bedside Monitor and Accessories per 510(k) K011918, commercial distribution certification dated September 12, 2001 and BSM-6000 Series Bedside Monitor per 510(k) K080342, commercial distribution certification date February 26, 2008.
#### Intended Use:
This device is intended to monitor, display and record physiological data to provide cardiac and vital signs monitoring within a medical facility. The device is intended to monitor the electrocardiogram and generate visible and/or audible alarms when an arrhythmia exists. The device is also intended to monitor heart rate, pulse rate, blood oxygen saturation (SpO2), noninvasive blood pressure (NIBP), invasive blood pressure (IBP), body temperature, carbon dioxide concentration (CO2 and EtCO2), and respiratory rate. The device may generate an audible and/or visible alarm when a measured rate falls outside preset limits. The device may also condition and transmit physiological signals via radio frequency. This will be available for use by medical personnel on all patient populations.
#### A summary of the technological characteristics of the device compared to the predicate device:
The CGS-9001A Series Communication Gateway Server is an Optional Accessory to the BSM-2300A and BSM-6000 Bedside Monitors, it is a software product that allows the Nihon Kohden Patient Monitoring System to transfer alarm event information from the monitoring device to a third party system. The Communication Gateway Server collects alarm information from all networked patient monitors in a Nihon Kohden Patient Monitoring System and forwards it to a commercially available third party Secondary Alarm Notification System. The alarm notification generated by the third party alarm (not marketed by Nihon Kohden America, Inc.) is for Secondary Alarm Notification Only.
DEC 2 4 2008
{1}------------------------------------------------
#### Performance Testing
- The device complies with IEC 601-1 sub-clause 56.2(c) implemented by 21 CFR . Part 868 Performance Standard for Electrode Lead Wires and Patient Cables. To date, no other special controls or performance standards are known or established for this device.
- The device is not sterile. .
- The device does not directly contact patients. Therefore, good laboratory practice . studies were not required per 21 CFR Part 58.
- The BSM-2300A and BSM-6000 Bedside Monitors with CGS-9001A Series . Communication Gateway Server Optional Accessory is a new device.
- The BSM-2300A and BSM-6000 Bedside Monitors with the CGS-9001A Series . Communication Gateway Server Accessory was subjected to safety and performance testing procedures. These tests verified that the device performed within specifications.
- Therefore. Nihon Kohden US Lab believes that the device is substantially . equivalent to the Nihon Kohden predicate device as stated.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image is a seal for the Department of Health & Human Services. The seal is circular, with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. In the center of the seal is an abstract image of an eagle with its wings spread. The eagle is facing to the right.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
## DEC 2 4 2008
Nihon Kohden America, Inc. c/o Mr. Jack Coggan Director of Regulatory Affairs/Quality Assurance 90 Icon Street Foothill Ranch, California 92610-1601
Re: K083271
Trade Name: BSM-2300A and BSM-6000 Bedside Monitors with CGS-9001A Series Communication Gateway Server Optional Accessory Regulation Number: 21 CFR 870.1025 Regulation Name: Arrhythmia detector and alarm Regulatory Class: Class II (two) Product Code: MHX Dated: December 10, 2008 Received: December 12, 2008
#### Dear Mr. Coggan:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration,
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must
{3}------------------------------------------------
Page 2- Mr. Jack Coggan
comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Bram D. Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health
Enclosure
{4}------------------------------------------------
#### G. Indications for Use Statement:
KOB3271 510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________
Device Name: The BSM-2300A and BSM-6000 Bedside Monitors with the CGS-9001A Series Communication Gateway Server Optional Accessory
#### Indications for Use:
The device is intended to monitor, display and record physiological data to provide cardiac and vital signs monitoring within a medical facility. The device is intended to monitor the electrocardiogram to generate audible and/or visible alarms when an arrhythmia exists. The device is also intended to monitor heart rate, pulse rate, blood oxygen saturation (SpO2), noninvasive blood pressure (NIBP), invasive blood pressure (IBP), body temperature, carbon dioxide concentration (CO2 and EtCO2), and respiratory rate. The device may generate an audible and/or visible alarm when a measured rate falls outside preset limits. The device may also condition and transmit physiological signals via radio frequency. This will be available for use by medical personnel on all patient populations.
Prescription Use: X (Part 21 CFR 801 Subpart D)
and/or
Over the Counter Use: (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
CONCURRANCE OF CDRH, OFFICE OF DEVICE EVALUATION (ODE)
eamall.
Division Sian-Off Division of Cardiovascular Devices K083271 510(k) Number
Panel 1
/
Sort by
Ready
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.